CTOs on the Move

Gyroscope Therapeutics

www.gyroscopetx.com

 
Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.gyroscopetx.com
  • 2200 Renaissance Boulevard Suite 410
    King of Prussia, PA USA 19406
  • Phone: 267.523.2100

Executives

Name Title Contact Details

Similar Companies

Enveda Biosciences

At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses nature`s complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics.

Bactrin International

Bactrin International is a Belgrade, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Passage Bio

Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc.is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.

Arrivo BioVentures

We are a biopharmaceutical company focused on accelerating biologics and small molecules through clinical development that have the potential to improve patient lives. We are a team of seasoned pharmaceutical and start-up professionals with an extensive track record of success. Our expertise is in fast, efficient and high quality drug development. Whether developing a reformulated product or a new chemical entity, our management team has expertise to identify regulatory strategies to expedite the path to approval through efficient clinical programs.